On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy

• Authors: Sai Mummareddy, Emory University; Stuti Pradhan, University of California, Los Angeles; Ashwin Kumar Narasimhan, SRM Institute of Science and Technology; Arutselvan Natarajan, Stanford University
• Journal Title: Biosensors
• Volume: Volume 11, Number 12
• Publisher: MDPI AG | 2021-12-07
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.3390/bios11120500
• Subjects: Engineering, Biomedical; Health Sciences, Immunology; Biology, Microbiology
• Keywords: cancer markers; immune checkpoints; PD-1; PD-L1

Abstract

Recently, considerable interest has emerged in the development of biosensors to detect biomarkers and immune checkpoints to identify and measure cancer through liquid biopsies. The detection of cancer biomarkers from a small volume of blood is relatively fast compared to the gold standard of tissue biopsies. Traditional immuno-histochemistry (IHC) requires tissue samples obtained using invasive procedures and specific expertise as well as sophisticated instruments. Furthermore, the turnaround for IHC assays is usually several days. To overcome these challenges, on-demand biosensor-based assays were developed to provide more immediate prognostic information for clinicians. Novel rapid, highly precise, and sensitive approaches have been under investigation using physical and biochemical methods to sense biomarkers. Additionally, interest in understanding immune checkpoints has facilitated the rapid detection of cancer prognosis from liquid biopsies. Typically, these devices combine various classes of detectors with digital outputs for the measurement of soluble cancer or immune checkpoint (IC) markers from liquid biopsy samples. These sensor devices have two key advantages: (a) a small volume of blood drawn from the patient is sufficient for analysis, and (b) it could aid physicians in quickly selecting and deciding the appropriate therapy regime for the patients (e.g., immune checkpoint blockade (ICB) therapy). In this review, we will provide updates on potential cancer markers, various biosensors in cancer diagnosis, and the corresponding limits of detection, while focusing on biosensor development for IC marker detection.